Opus Genetics, Inc. Notes Payable, Fair Value Disclosure
Opus Genetics, Inc. (IRD) had Notes Payable, Fair Value Disclosure of $1.30 million as of 2021-12-31, per its 10-K filed 2022-03-24.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures
us-gaap:NotesPayableFairValueDisclosure · last filed 2022-03-24
- 2021-12-31: Notes Payable, Fair Value Disclosure $1.30M.
- 2020-12-31: Notes Payable, Fair Value Disclosure $1.30M.
- 2020-09-30: Notes Payable, Fair Value Disclosure $1.26M.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2021-12-31 | $1.30M 10-K · filed 2022-03-24 |
| 2020-12-31 | $1.30M 10-K · filed 2021-03-11 |
| 2020-09-30 | $1.26M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |